Decisions made throughout early and mid-stage clinical trials impact late-stage results and sometimes, entire programs and companies. Since some obstacles can prove overwhelming for startups, there is a lot to learn from those who successfully walked the path.
Meredith Perry is Director of Pharmaceutics at Catalent San Diego. Since 2012 Ms. Perry has developed a wide range of preclinical and early phase clinical formulations, joining Catalent in 2017. She focuses on helping clients to navigate the product development strategies unique to the early development of new therapies. Ms. Perry holds bachelor’s in both Chemistry and Economics from the University of California, San Diego.
Scott Braunstein, M.D. was appointed Chief Executive Officer of Marinus in August 2019, executive chairman in February 2019 and has served on our board since September 2018. Dr. Braunstein brings over 20 years of knowledge and experience from diverse biotechnology and pharmaceutical industry vantage points. Dr. Braunstein is currently an operating partner at Aisling Capital. He most recently served as chief strategy officer and chief operating officer at Pacira Biosciences, Inc. Prior to Pacira, Dr. Braunstein served as a healthcare portfolio manager at Everpoint Asset Management and spent 13 years with J.P. Morgan Asset Management as a healthcare analyst and managing director in the U.S. Equity team, and as portfolio manager of the JP Morgan Global Healthcare Fund responsible for managing investments in pharmaceuticals, biotechnology and medical devices.
Dr. Braunstein is currently on the board at Trevena, Inc. and Caribou Biosciences, Inc. He previously served on the boards of Constellation Pharmaceuticals (acquired by MorphoSys AG in July 2021), Ziopharm Oncology, Inc., Esperion Therapeutics, Inc. and Protara Therapeutics, Inc. Dr. Braunstein began his career as a practicing physician at the Summit Medical Group and as assistant clinical professor at Albert Einstein College of Medicine and Columbia University Medical Center. He earned his medical degree from the Albert Einstein College of Medicine and his B.S. from Cornell University.
Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.